Skip to main content
. 2012 May 17;13(5):401–406. doi: 10.1007/s10194-012-0455-4

Fig. 1.

Fig. 1

Cumulative hazard of recurrence over the 24 h during treatment with frovatriptan (continuous line) or almotriptan (dashed line) in the 67 women with menstrually related migraine included in this analysis. The p value refers to the statistical significance of the between-treatment difference